Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
LianBio LIAN
$2.14
-$0.06 (-2.73%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
242350611.00000000
-
week52high
3.33
-
week52low
1.07
-
Revenue
0
-
P/E TTM
-2
-
Beta
0.00000000
-
EPS
-0.98000000
-
Last Dividend
0.00000000
-
Next Earnings Date
27 мар 2023 г. в 12:37
Описание компании
LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor for ulcerative colitis and Crohn's disease; NX-13 for ulcerative colitis; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus. It has a partnership with Tarsus Pharmaceuticals, Inc. to develop and commercialize TP-03, an eye solution for the treatment of Demodex blepharitis; and Nanobiotix S.A. to develop and commercialize NBTXR3, a radioenhancer designed to be injected directly into a malignant tumor prior to standard radiotherapy. The company was incorporated in 2019 and is headquartered in Princeton, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Jefferies | Buy | 26 ноя 2021 г. | |
| Goldman Sachs | Neutral | 26 ноя 2021 г. | |
| Raymond James | Outperform | 24 ноя 2021 г. | |
| Raymond James | Outperform | Outperform | 14 окт 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wang Yizhe | A | 1292324 | 1292324 | 20 янв 2023 г. |
| QIAN JIANG | A | 318995 | 318995 | 20 янв 2023 г. |
| Jahn Brianne | A | 318995 | 318995 | 20 янв 2023 г. |
| Larson Yi | A | 464099 | 464099 | 20 янв 2023 г. |
| QIAN JIANG | D | 67349 | 2239 | 03 янв 2023 г. |
| PERCEPTIVE ADVISORS LLC | A | 3728491 | 998240 | 18 авг 2022 г. |
| Poukalov Konstantin | A | 36300 | 36300 | 23 июн 2022 г. |
| PERCEPTIVE ADVISORS LLC | A | 36000 | 36000 | 23 июн 2022 г. |
| Stone Adam Leo | A | 36300 | 36300 | 23 июн 2022 г. |
| Silbermann Susan Michele | A | 36300 | 36300 | 23 июн 2022 г. |
Новостная лента
LianBio (LIAN) Up After Pfizer Opts in Rights to RSV Drug in China
Zacks Investment Research
20 дек 2022 г. в 12:02
As a result of Pfizer's (PFE) opt-in for LianBio's (LIAN) rights to develop RSV therapeutic candidate sisunatovir in Greater China, the latter is eligible to receive potential royalties and milestone payments.
Penny Stocks To Buy Now? 6 To Watch With Big News Today
PennyStocks
19 дек 2022 г. в 09:33
Hot penny stocks to watch with big news this week. The post Penny Stocks To Buy Now?
Best Penny Stocks To Buy Now? 4 To Watch As APE Stock Goes Public
PennyStocks
22 авг 2022 г. в 11:24
Hot penny stocks to watch but are they a buy now or not? Let's look at the catalysts.
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
Seeking Alpha
02 мар 2022 г. в 23:41
LianBio: An Undervalued Play On The $220B/Year Chinese Pharmaceutical Market
LianBio Stock (LIAN): Why The Price Surged Today
Pulse2
11 янв 2022 г. в 19:22
The stock price of LianBio (NASDAQ: LIAN) increased by 19.67% today. This is why it happened.